Karyopharm Therapeutics Inc. 25K.F Stock
Karyopharm Therapeutics Inc. Price Chart
Karyopharm Therapeutics Inc. 25K.F Financial and Trading Overview
Karyopharm Therapeutics Inc. stock price | 1.21 EUR |
Previous Close | 1.87 EUR |
Open | 1.85 EUR |
Bid | 1.86 EUR x 100000 |
Ask | 1.93 EUR x 100000 |
Day's Range | 1.85 - 1.85 EUR |
52 Week Range | 1.85 - 5.97 EUR |
Volume | 1.8K EUR |
Avg. Volume | 56 EUR |
Market Cap | 211.43M EUR |
Beta (5Y Monthly) | 0.041901 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.17 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 15.22 EUR |
25K.F Valuation Measures
Enterprise Value | 263.96M EUR |
Trailing P/E | N/A |
Forward P/E | -0.91354686 |
PEG Ratio (5 yr expected) | 0.07 |
Price/Sales (ttm) | 1.4276077 |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | 1.782 |
Enterprise Value/EBITDA | -2.119 |
Trading Information
Karyopharm Therapeutics Inc. Stock Price History
Beta (5Y Monthly) | 0.041901 |
52-Week Change | -46.34% |
S&P500 52-Week Change | 20.43% |
52 Week High | 5.97 EUR |
52 Week Low | 1.85 EUR |
50-Day Moving Average | 2.86 EUR |
200-Day Moving Average | 3.73 EUR |
25K.F Share Statistics
Avg. Volume (3 month) | 56 EUR |
Avg. Daily Volume (10-Days) | 180 EUR |
Shares Outstanding | 114.01M |
Float | 102.49M |
Short Ratio | N/A |
% Held by Insiders | 5.02% |
% Held by Institutions | 90.23% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -106.69% |
Operating Margin (ttm) | -84.61% |
Gross Margin | 97.22% |
EBITDA Margin | -84.11% |
Management Effectiveness
Return on Assets (ttm) | -25.27% |
Return on Equity (ttm) | N/A |
Income Statement
Revenue (ttm) | 148.1M EUR |
Revenue Per Share (ttm) | 1.63 EUR |
Quarterly Revenue Growth (yoy) | -18.80% |
Gross Profit (ttm) | 151.86M EUR |
EBITDA | -124581000 EUR |
Net Income Avi to Common (ttm) | -158018000 EUR |
Diluted EPS (ttm) | -1.62 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 260.38M EUR |
Total Cash Per Share (mrq) | 2.28 EUR |
Total Debt (mrq) | 311.31M EUR |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 5.175 |
Book Value Per Share (mrq) | -0.396 |
Cash Flow Statement
Operating Cash Flow (ttm) | -109267000 EUR |
Levered Free Cash Flow (ttm) | -50634624 EUR |
Profile of Karyopharm Therapeutics Inc.
Country | Germany |
State | MA |
City | Newton |
Address | 85 Wells Avenue |
ZIP | 02459 |
Phone | 617 658 0600 |
Website | https://www.karyopharm.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 385 |
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company is also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Q&A For Karyopharm Therapeutics Inc. Stock
What is a current 25K.F stock price?
Karyopharm Therapeutics Inc. 25K.F stock price today per share is 1.21 EUR.
How to purchase Karyopharm Therapeutics Inc. stock?
You can buy 25K.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Karyopharm Therapeutics Inc.?
The stock symbol or ticker of Karyopharm Therapeutics Inc. is 25K.F.
Which industry does the Karyopharm Therapeutics Inc. company belong to?
The Karyopharm Therapeutics Inc. industry is Biotechnology.
How many shares does Karyopharm Therapeutics Inc. have in circulation?
The max supply of Karyopharm Therapeutics Inc. shares is 115.07M.
What is Karyopharm Therapeutics Inc. Price to Earnings Ratio (PE Ratio)?
Karyopharm Therapeutics Inc. PE Ratio is now.
What was Karyopharm Therapeutics Inc. earnings per share over the trailing 12 months (TTM)?
Karyopharm Therapeutics Inc. EPS is -1.17 EUR over the trailing 12 months.
Which sector does the Karyopharm Therapeutics Inc. company belong to?
The Karyopharm Therapeutics Inc. sector is Healthcare.